News

Featured News

  • Categories: News | Published On: June 12, 2024 |

    Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

  • Categories: News | Published On: June 3, 2024 |

    Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany.

  • Categories: News | Published On: April 24, 2024 |

    Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

Filter by:
  • Categories: Publication | Published On: July 10, 2024 |

    A novel therapeutically active anti-TNFR2 agonistic antibody promotes Treg proliferation and induction of Treg functional markers

  • Categories: News | Published On: June 12, 2024 |

    Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

  • Categories: News | Published On: June 3, 2024 |

    Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany.

  • Categories: Publication | Published On: May 14, 2024 |

    A Novel Computationally Designed Multibody Targeting IL-13/TSLP for Precision Therapy in TH2-Mediated Diseases

  • Categories: News | Published On: April 24, 2024 |

    Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

  • Categories: News | Published On: December 18, 2023 |

    Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors

  • Categories: News | Published On: December 14, 2023 |

    Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

  • Categories: Publication | Published On: September 9, 2023 |

    Redirecting an anti-IL-1β antibody to bind a new, unrelated and computationally predicted epitope on hIL-17A

  • Categories: Publication | Published On: June 23, 2023 |

    Accurate profiling of full-length Fv in highly homologous antibody libraries using UMI tagged short reads

  • Categories: Publication | Published On: March 29, 2023 |

    Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2

  • Categories: News | Published On: August 23, 2022 |

    The Logical Song: Biolojic Design Reimagines Antibodies into “Smart” Therapeutics

  • Categories: News | Published On: April 5, 2022 |

    First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients

  • Categories: Publication | Published On: November 10, 2021 |

    The computationally designed human antibody, AU-007, mediates human immune activation by endogenous IL-2, while uniquely breaking the IL-2 auto-inhibitory loop and preventing Treg expansion

  • Categories: News | Published On: March 8, 2021 |

    Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes

  • Categories: News | Published On: February 25, 2021 |

    Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease

  • Categories: Publication | Published On: February 21, 2021 |

    Biolojic’s anti IL2 antibody covered in Nature’s review of current IL2 therapies in development

  • Categories: News | Published On: February 18, 2021 |

    Restoring IL-2 to its cancer immunotherapy glory

  • Categories: Publication | Published On: November 20, 2018 |

    Computational Design of Epitope-Specific Functional Antibodies